Abstract
This study compared overall survival (OS) in patients receiving nivolumab + low-dose ipilimumab in CheckMate 142 versus patients in the real world (RW) receiving standard of care (SOC) therapy for second-line and later (2L+) microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC). CheckMate 142 is an ongoing, multi-cohort, nonrandomized phase 2 trial, and these results contextualize survival outcomes for Cohort 2 nivolumab + low-dose ipilimumab versus SOC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
